Adalimumab-Induced Minimal Change Disease

Author(s): Boyan Xia, Mary Salim, Eugenio Capitle

Tumor Necrosis Factor inhibitors are frequently used for treatment of rheumatic and other inflammatory diseases. These medications are generally well tolerated and have shown great efficacy for treatment of Rheumatoid Arthritis [1].

Though nephrotic syndrome and renal injury can occur secondary to medications, anti-TNFα agents are rarely associated with nephrotoxicity [2]. Here we report a case of a patient who presented with generalized edema and ultimately found to have adalimumab induced minimal change disease (MCD).